作者投稿
专家审稿
编辑办公
邮件订阅
RSS
Whether Elderly Patients with Her-2 Positive Breast Cancer but Without Heart Disease Should Receive Targeted Therapy?
-
摘要: 随着我国人口老龄化，乳腺癌治疗需要面对更多的老年患者。近年来，靶向治疗作为人表皮生长因子受体2(human epidermal growth factor receptor 2，HER-2)阳性乳腺癌全身治疗的重要方法，在乳腺癌治疗中的地位越来越重要。无心脏基础疾病的老年HER-2阳性乳腺癌患者是否应使用曲妥珠单克隆抗体进行靶向治疗存在争议。目前证据表明，60~70岁老年HER-2阳性乳腺癌患者可从曲妥珠单克隆抗体治疗中获益，心脏事件风险较低且可逆，但70岁以上患者目前无大规模试验证据支持。在选择辅助治疗方案时需平衡获益与风险，综合考虑患者本人意愿和身体状况，进行个体化治疗。若治疗选择曲妥珠单克隆抗体，需避免与蒽环类化疗药物联用并监测心功能，及时发现和处理心脏事件。Abstract: With a nationwide increase in elderly population, an increased number of breast cancer diagnosed in older women is expected. Nowadays, targeted therapy is an important systemic treatment for human epidermal growth factor 2 (HER-2) positive breast cancer, which has been playing an important role in the treatment for breast cancer. It is controversial whether trastuzumab should be used for targeted therapy in elderly Her-2 positive breast cancer patients with moderate risk and no cardiac disease. Current evidence suggests that patients aged 60-70 years old with a moderate risk of Her-2 positive breast cancer may benefit from trastuzumab with an acceptable and reversible risk of heart events. Yet there is no enough evidence for elderly patients beyond 70 years old. Therefore, we should balance the benefit and risk when considering targeted therapy for elderly patients with breast cancer. Management of breast cancer in the elderly should take the will of the patients, the physical condition, and comorbidities in to consideration. Anthracycline-based chemotherapy should not be used together with targeted therapy. It is necessary to monitor cardiac function and deal with heart events timely.
-
Keywords:
- old women /
- breast cancer /
- targeted therapy
-
目前, 我国每年新增肝癌患者数约占全世界新增肝癌的54%[1], 年死亡率20.4 /10万人, 占全世界肝癌死亡人数的40%。而肝脏占位的早期正确诊断是选择合适的治疗方案, 改善疾病预后的关键。临床上通过各种血清学检查、超声、CT和MRI及相关增强影像, 可使绝大多数肝脏占位能在术前明确性质, 但仍有少部分肝脏占位通过上述检查不能做出诊断, 给治疗方案的制定带来了一定的困难。本研究选取40例经全面术前检查仍不能明确诊断, 同时又有条件进行两次不同正电子发射计算机断层显像(positronemissiontomography, PET)检查的肝脏占位患者, 比较18 F-去氧葡萄糖(18 F-fluorodeoxyglucose, 18 F-FDG)和11 C-乙酸盐(11 C-Acetate)两种示踪剂PET对肝脏占位诊断的价值。
对象和方法
对象
从本科2004年10月至2010年8月经术前血清学检查, 如甲胎蛋白(α-fetoprotein, AFP)测定、B超、CT、MRI及相关增强技术仍无法明确诊断的肝脏占位患者中选取40例纳入本研究, 于术前行18 FFDG和11 C-Acetate两种示踪剂PET检查。40例患者中, 男性30例, 女性10例; 年龄31 ~ 74岁, 平均55.1岁。HBsAg(+)患者24例, HCV (+) 3例。术前肝功能分级:ChildA级37例, ChildB级3例。病例选取条件:(1)检查前均未行手术、放疗、化疗及其他治疗; (2)血清学检查、B超、CT、MRI及相关增强技术未能明确占位性质, 但临床高度怀疑恶性肿瘤; (3)全身情况、肝功能可耐受相应切除范围的手术。
方法
所有患者在行PET前均签署知情同意书, 分别在第1天和第2天空腹6 h后接受18 F-FDG-PET和11C-Acetate-PET扫描, 所用仪器为SIEMENS/CTIEXACTHR+。分别在静脉注射18 F-FDG后1 h、静脉注射11C-Acetate后10 min为扫描点, 根据肿物放射性曲线所得到的SUV值与等面积的正常肝脏组织SUV值比较, 比值≤1.0提示良性, >1.0提示恶性可能性大。
统计学处理
采用SPSS12.0统计软件, 分类变量比较采用χ2检验或配对χ2检验, 可信区间95%, P < 0.05表示差异有统计学意义。
结果
40例肝脏占位患者中39例行手术治疗, 1例经皮肝穿刺获取肿物组织。
术后病理结果
术后病理证实:40例肝脏占位患者中原发性肝细胞肝癌28例, 肝内胆管细胞癌3例, 肝血管肉瘤1例, 恶性神经内分泌肿瘤1例, 肝硬化结节伴不典型增生2例, 血管平滑肌脂肪瘤1例, 海绵状血管瘤1例, 局灶性结节性增生(FNH) 1例, 胆囊黄色肉芽肿2例。在35例恶性肿瘤和癌前病变中, 低分化7例, 中低分化5例, 中分化9例, 中高分化4例, 高分化8例, 不典型增生2例。
术前影像学及PET扫描结果
术前影像学及PET扫描结果显示:经术后病理证实的35例恶性肝脏病变和癌前病变中34例均显示病变局限于肝脏组织, 1例显示有门脉转移; 其中18F-FDG诊断恶性20例, 良性15例, 18 F-FDG对恶性病变的敏感性为57.1%, 阳性预测值为100%; 11 C-Acetate诊断恶性病变29例, 良性病变6例, 11 CAcetate对恶性病变的敏感性为82.9%, 阳性预测值为90.6%;而联合双示踪剂诊断恶性病变34例, 良性病变1例, 其对恶性病变的敏感性为97.1%, 阳性预测值为91.9%, 双示踪剂联合应用敏感性明显增加(表 1)。
表 1 肝脏占位患者正电子发射计算机断层显像结果
35例恶性肝脏病变和癌前病变中, 肿瘤最大直径 < 3 cm者18例, PET发现17例; 肿瘤最大直径≥3 cm者17例, PET发现15例, 双示踪剂PET检测小肝癌与非小肝癌发现率比较差异无统计学意义(χ2检验, χ2 =0.430, P=0.512) (表 2)。
表 2 恶性肝脏病变和癌前病变大小与正电子发射计算机断层显像结果
两种示踪剂对不同分化程度恶性肿瘤的阳性显示率不同。对于不典型增生、高分化及中高分化肝脏恶性肿瘤, 11 C-Acetate的敏感性为100%, 18F-FDG的敏感性为28.6%, 两者比较差异有显著统计学意义(配对χ2检验, χ2 =8.100, P < 0.01)。而对于低分化、中低分化肝脏恶性肿瘤, 11C-Acetate的敏感性为58.3%, 18 FFDG的敏感性为75.0%, 两者比较差异无统计学意义(配对χ2检验, χ2 =2.857, P=0.091) (表 3)。
表 3 肝脏占位病理分化程度和正电子发射计算机断层显像结果
讨论
PET是目前唯一可以了解组织分子生物学代谢改变的影像技术。通过不同的示踪剂, PET显像能体现细胞内不同分子的代谢信息, 为诊断提供依据。有报道显示PET对于原发肿瘤不明的诊断敏感性达84% ~ 93.6%[2-3], 但对肝脏原发性肿瘤诊断的报道结果并不一致, 甚至存在40% ~ 50%的假阴性率[4-7]。本研究对常规检查不能确诊的肝脏占位患者, 试图通过两种不同的PET检查以提高肝癌的术前诊断率, 并依据PET示踪剂的生物学代谢特点判断肿瘤的分化程度。
应用18 F-FDG做为PET示踪剂, 可以评价细胞内糖类的代谢。在过去的10余年中, 18 F-FDG-PET已成功地用于区分良性病变和恶性肿瘤、判定肿瘤复发、指导肿瘤分期等[6]。但在部分肝细胞肝癌中, 糖酵解并非最佳代谢途径, 其与间质组织或正常肝脏细胞类似, 因此应用PET诊断时容易出现误诊[4, 7-8]。本研究结果显示, 18 F-FDG-PET诊断肝脏恶性肿瘤的敏感性为57.1%, 阳性预测值为100%, 显示出其临床应用价值。事实上, 18 F-FDG在细胞中的代谢取决于磷酸酶和葡萄糖-6-磷酸酶的活性。在正常肝组织和分化程度好的肝细胞肝癌中, 葡萄糖-6-磷酸酶水平相对较高, FDG磷酸盐的去磷酸化相对较快, FDG在细胞内的蓄积较少[9], 因而对于分化程度好的肝癌, 18 F-FDG-PET显像与周围肝组织类似, 从而降低了其敏感性[4, 8]。本研究结果也提示, 18 F-FDG-PET检测不典型增生、高分化、中高分化肝脏恶性肿瘤的敏感性较低, 仅为28.6%;而对于低分化和中低分化肝脏恶性肿瘤, 其敏感性可高达75.0%。
11 C-Acetate作为示踪剂是近年来才开始在PET中应用的, 其首先应用于心血管、神经、泌尿系统的疾病诊断[10]。11 C-Acetate是β氧化的代谢底物, 脂肪酸和胆固醇的前体[11], 通过细胞的脂肪酸合成而进入肿瘤组织。已有文献证实11 C-Acetate-PET能用于多种恶性肿瘤的定性诊断。目前国际上应用11 C-Acetate- PET诊断肝脏肿瘤正处于起步阶段[4-5, 12-13], 在国内除本研究小组前期的报道外[14-15], 尚很少有类似报道。本研究结果显示, 11 C-Acetate-PET诊断肝脏恶性肿瘤的诊断敏感性为82.9%, 阳性预测值为90.6%, 与Ho及Park等[4, 13]报道类似, 显示出Acetate对于疑难肝脏占位的高敏感性。另一方面, 11 C-Acetate- PET对于不典型增生、高分化和中高分化肝脏恶性肿瘤的诊断敏感性为100%, 且与18 F-FDG-PET比较具有显著差异, 提示其有可能弥补18 F-FDG-PET对于中高分化程度恶性肿瘤敏感性低的劣势[8]; 而对于低分化和中低分化肝脏恶性肿瘤, 其敏感性仅为58.3%, 低于18 F-FDG-PET, 但两者比较差异无显著统计学意义, 这可能受限于病例数较少。
两种PET示踪剂的代谢方式不一样, 因此联合应用18F-FDG和11 C-Acetate进行PET扫描, 或许可以起到相互补充的作用。本研究结果显示。联合应用两种示踪剂的敏感性为97.1%, 阳性预测值为91.9%, 提高了肝脏恶性肿瘤的术前诊断率; 且两者联合应用, 有可能提示肿瘤的分化程度, 更好地指导诊断和治疗[4, 13]。
如前所述, PET检查主要取决于肿物组织内的分子代谢, 而非肿物体积。本研究应用双示踪剂PET检测, 对于小肝癌与非小肝癌的发现率无显著性差异。
综上, 对于临床上无法明确诊断的肝脏占位, PET检查虽然价格昂贵, 但仍显示了一定的优势。联合应用18 F-FDG-PET和11 C-Acetate-PET可以增加肝癌诊断的敏感性, 提高术前诊断率。根据两种示踪剂阳性不同, 可能提示恶性肿瘤的分化程度, 这对治疗方案的选择也有一定的指导意义。本研究尚需进一步累积病例, 以减少因样本量少而产生的偏倚。
利益冲突 无 -
[1] Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015, 372:134-141. DOI: 10.1002/ijc.29210
[2] DeSantis CE, Fedewa SA, Goding Sauer A, et al.Breast cancer statistics 2015: convergence of incidence rates between black and white women [J].CA Cancer J Clin, 2016, 66:31-42. DOI: 10.3322/caac.21320
[3] Ma C, Zhou Q, Nie X, et al.Breast cancer in Chinese elderly women: pathological and clinical characteristics and factors influencing treatment patterns [J]. Crit Rev Oncol Hematol, 2009, 71: 258-265. DOI: 10.1016/j.critrevonc.2008.11.005
[4] Hamaker ME, Schreurs WH, Uppelschoten JM, et al. Breast cancer in the elderly: retrospective study on diagnosis and treatment according to national guidelines [J].Breast, 2009, 15: 26-33. DOI: 10.1111/j.1524-4741.2008.00667.x
[5] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: breast cancer(Version1.2018) [EB/OL]. https: //www.nccn.org/professionals/physician_gls/default.aspx#breast. https://www.nccn.org/professionals/physician_gls/default.aspx
[6] Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer[J].Clin Oncol, 2013, 31:4222-4228. DOI: 10.1200/JCO.2013.48.7884
[7] World Health Organization. Mental Health of older adults[EB/OL]. http://www.who.int/news-room/fact-sheets/detail/mental-health-of-older-adults" target=_blank> http://www.who.int/news-room/fact-sheets/detail/mental-health-of-older-adults.
[8] Biganzoli L, Wildiers H, Oakman C, et al.Management of elderly patients with breast cancer: updated re-commendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA) [J]. Lancet Oncol, 2012, 13:e148-e160. https://www.sciencedirect.com/science/article/pii/S1743919114008280
[9] Schonberg MA, Marcantonio ER, Li D, et al.Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival [J]. Clin Oncol, 2010, 28: 2038-2045. DOI: 10.1200/JCO.2009.25.9796
[10] Wildiers H, Van Calster B, van de Poll-Franse LV, et al. Relationship between age and axillary lymph node involve-ment in women with breast cancer[J]. Clin Oncol, 2009, 27: 2931-2937. DOI: 10.1200/JCO.2008.16.7619
[11] Rosso S, Gondos A, Zanetti R, et al. Up-to-date estimates of breast cancer survival for the years 2000－2004 in 11 European countries: the role of screening and a comparison with data from the United States[J]. Eur J Cancer, 2010, 46: 3351-3357. DOI: 10.1016/j.ejca.2010.09.019
[12] Bastiaannet E, Liefers GJ, de Craen AJM, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127, 805 unselected pa- tients [J]. Breast Cancer Res Treat, 2010, 124: 801-807. DOI: 10.1007/s10549-010-0898-8
[13] Neuner JM, Zokoe N, McGinley EL, et al. Quality of life among a population-based cohort of older patients with breast cancer[J]. Breast, 2014, 23: 609-616. DOI: 10.1016/j.breast.2014.06.002
[14] Hurria A, Dale W, Mooney M, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 Conference Recommendations [J]. Clin Oncol, 2014, 32: 2587-2594. DOI: 10.1200/JCO.2013.55.0418
[15] Derks MGM, Kiderlen M, Bastiaannet E, et al. Large variation in treatment of older patients with nonmetastatic breast cancer in Europe: a population based cohort study from the EURECCA Breast Cancer Group[J]. Lancet Oncol, 2018 (unpublished manuscript). https://pubmed.ncbi.nlm.nih.gov/29875471/
[16] Goldhirsch A, Wood WC, Gelber RD, et al.Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer [J]. Ann Oncol, 2007, 18:1133-1144. DOI: 10.1093/annonc/mdm271
[17] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer[J].N Engl J Med, 2005, 353:1659-1672. DOI: 10.1056/NEJMoa052306
[18] Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial [J].Lancet Oncol, 2011, 12:236-244. DOI: 10.1016/S1470-2045(11)70033-X
[19] Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer [J].N Engl J Med, 2011, 365:1273-1283. DOI: 10.1056/NEJMoa0910383
[20] Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31[J].Clin Oncol, 2011, 29:3366-3373. DOI: 10.1200/JCO.2011.35.0868
[21] Cameron D, Piccart-Gebhart MJ, Gelber RD, et al.11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. Lancet, 2017, 389:1195-1205. DOI: 10.1016/S0140-6736(16)32616-2
[22] Perez EA, Romond EH, Suman VJ, et al.Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. Clin Oncol, 2014, 32:3744-3752. DOI: 10.1200/JCO.2014.55.5730
[23] Brollo J, Curigliano G, Disalvatore D, et al.Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials [J].Cancer Treat Rev, 2013, 39:44-50. DOI: 10.1016/j.ctrv.2012.03.009
[24] Michel M, Francesco C, Dominique M, et al. Randomized Phase II Trial of the efficacy and safety of Trastuzumab combined with Docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:the M77001 study group [J].J Clin Oncol, 2005, 23:4265-4274. https://reference.medscape.com/medline/abstract/15911866
[25] de Azambuja E, Bedard PL, Suter T, et al. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? [J]. Target Oncol, 2009, 4:77-88. DOI: 10.1007/s11523-009-0112-2
[26] de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herception adjuvant trial(BIG 1-01)[J]. Clin Oncol, 2014, 32:2159-2165.
[27] Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel(ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer[J]. Clin Oncol, 2012, 30:3792-3799. DOI: 10.1200/JCO.2011.40.0010
[28] Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes [J]. Biol Chem, 1998, 273:10261-10269. DOI: 10.1074/jbc.273.17.10261
[29] Dall P, Lenzen G, Göhler T, et al. Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany[J] J Geriatr Oncol, 2015, 6:462-469. DOI: 10.1016/j.jgo.2015.06.003
[30] Tolaney SM, Barry WT, Dang CT, et al.Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer[J].N Engl J Med, 2015, 372:134-141. DOI: 10.1056/NEJMoa1406281
[31] Du XL, Xia R, Burau K, et al. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005[J]. Med Oncol, 2010, 28:S80-S90. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=a063c87d6d3ab8053c62b723fd982162
[32] Curigliano G, Burstein HJ, P Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer[J].Anna Oncol, 2017, 28:1700-1712. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887963/
-
期刊类型引用(1)
1. 盛霞，秦建民. 肝脏不典型增生结节的临床特点及诊治策略. 世界华人消化杂志. 2022(04): 169-181 . 
百度学术
其他类型引用(0)
下载:
计量
- 文章访问数: 248
- HTML全文浏览量: 32
- PDF下载量: 78
- 被引次数: 1
